Manni Mohyuddin: Current trials must have observation/surveillance as control arm

Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared a post by
Multiple Myeloma Hub, on Twitter, adding the following:

“The majority of clinicians recommend against routine treatment of smoldering myeloma- instead preferring active surveillance.

Future/current trials must have observation/surveillance as control arm as that is the preferred/current standard of care.”

Quoting Multiple Myeloma Hub:

“Clinician preferences on the treatment of smoldering multiple myeloma, check out our key points below!

What treatment would you recommend for smoldering multiple myeloma? HCPs, share your thoughts below!”

Source: Manni Mohyuddin/Twitter and Multiple Myeloma Hub/Twitter